Review Article
Effects and Mechanisms of Five Psoralea Prenylflavonoids on Aging-Related Diseases

Yi-Ting Zhou,¹,² Lin Zhu,¹,² Yunyun Yuan,¹ Shuang Ling,¹ and Jin-Wen Xu¹

¹Institute of Interdisciplinary Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
²Clinical Medicine of Integrated Chinese and Western Medicine in Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Correspondence should be addressed to Shuang Ling; sarah_ling@126.com and Jin-Wen Xu; jwxu1001@163.com

Received 24 February 2020; Revised 12 May 2020; Accepted 28 May 2020; Published 18 June 2020

Academic Editor: Hassan Obied

Copyright © 2020 Yi-Ting Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

During the aging process, senescent cells gradually accumulate in the organs; they secrete proinflammatory cytokines and other factors, collectively known as the senescence-associated secretory phenotype (SASP). SASP secretions contribute to "inflammaging," which is a state of chronic, systemic, sterile, low-grade inflammatory microenvironment and a key risk factor in the development of aging-related diseases. Fructus psoraleae is a traditional Chinese medical herb best known for delaying aging and treating osteoporosis. Prenylflavonoids from fructus psoraleae are the main bioactive compounds responsible for its pharmacological applications, such as beaching, bavachinin, bavachalcone, isobavachalcone, and neobavaisoflavone. In previous decades, there have been some promising studies on the pharmacology of fructus psoraleae. Here, we focus on the anti-inflammatory and antiaging diseases of five psoralea prenylflavonoids, such as cardiovascular protection, diabetes and obesity intervention, neuroprotection, and osteoporosis, and discuss the mechanism of these active ingredients for better understanding the material basis and drug application of fructus psoraleae in Chinese medicine.

1. Introduction

Fructus psoraleae (补骨脂), a traditional Chinese medical herb, is the dried and mature fruit of Psoralea corylifolia Linn., which is an annual herb of Leguminosae (Figures 1(a)–1(c)). After drying, the psoraleae fruits are mixed with salt water and gently stir-baked until the fruits are slightly swollen. Then, the salt-processed fructus psoraleae could be used as a traditional Chinese medicine in the clinic. Fructus psoraleae is considered to have the efficacy of “relieving chronic morning diarrhea, warming and invigorating the Kidney-Yang, gathering the spirit, and enriching the bone marrow” in the Compendium of Materia Medica. According to the traditional Chinese medicine theories, fructus psoraleae has the function of delaying aging. The chemical constituents of fructus psoraleae mainly include coumarin, terpenoid phenols, and prenylflavonoids, which are the therapeutic material basis of fructus psoraleae. The structure of prenylflavonoids is characterized by the presence of isopentenyl side chains on the flavonoid skeletons. The structural types of isopentenyl are mainly 5 kinds of side chains: isopentenyl, hydroxyisopentenyl, pyran ring isopentenyl, lavender, and hydroxylavender. Most of psoralea prenylflavonoids are contained in ethyl acetate extract active fractions from Psoralea corylifolia [1, 2]. A recent study has shown that all the tested compounds in Psoralea corylifolia were absorbed into the blood plasma of rats rapidly, almost evenly distributed in the brain parenchyma, and the overall trend in the brain was basically similar to the results of plasma concentration time. Moreover, in terms of the ratio of total brain to plasma, isoprene flavonoids were easier to enter the brain than coumarin [3]. Another pharmacokinetic report also showed that rats taking oral administration and intraperitoneal injection with 20 mg/kg bavachalcone were detected with maximum plasma concentrations of 165 and 740 μg/L, with a drug half-life of 1 and 1.25 h, respectively [4]. Fructus psoraleae has certain hepatotoxicity mainly caused by its constituents, such as bakuchiol, psoralen, and isopsoralen [5, 6]. Some psoralea
Prenylflavonoids exhibited inhibitory effects on microsomal enzymes in *in vitro* experiments. For example, acyl CoA:cholesterol acyltransferase (ACAT), an enzyme that catalyzes the esterification of cholesterol in the intestine and the production of lipoproteins in the liver, was inhibited by bavachin and isobavachalcone [7]. The following are some similar reports: (1) neobavaisoflavone, isobavachalcone, bavachinin, corylifol A, and bakuchiol blocked human carboxylesterase 2 [8]; (2) bavachalcone, bavachin, and corylifol A strongly and neobavaisoflavone, isobavachalcone, and bavachinin moderately inhibiting UGT1A1 [9, 10]; and (3) psoralidin, isobavachalcone, and neobavaisoflavone inhibiting CYP2E1 mRNA expression. Meanwhile, isobavachalcone showed a weak competitive inhibition on CYP3A4, whereas psoralidin and neobavaisoflavone exhibited significant induction of CYP3A4 mRNA expression [11].

With the development of aging, senescent cells gradually accumulate in tissues, which produce proinflammatory factors and form a low-degree of sterility and potential systemic inflammation to result in aging-related diseases. This negatively affected microenvironment is called “inflammaging,” which is the key factor connecting cell aging and the development of aging-related diseases. Modern pharmacological studies showed that bavachin, bavachinin, bavachalcone, isobavachalcone, and neobavaisoflavone (Figure 1(d)) had various pharmacological actions and could improve aging-related diseases. In this paper, we will review the effects and mechanisms of these five psoralea prenyllavonoids on ameliorating aging-related diseases, such as aging-induced chronic low-grade inflammation, cardiovascular dysfunction, diabetes, and obesity, and improving neurodegenerative diseases and osteoporosis.

**Figure 1**: Fructus psoraleae and prenyllavonoid structures: (a) psoralea plants, (b) psoralea flowers, (c) Chinese herbal product of fructus psoraleae, and (d) prenyllavonoid structures.
2. Anti-Inflammatory Action

The accumulation of senescent cells with age causes a series of pathological manifestations. Nonproliferating cells occupy key cell niches and produce proinflammatory factors, which form a negatively affected microenvironment and present a senescence-associated secretory phenotype (SASP). SASP contributes to a state of sterile, systemic, low-grade inflammation, also known as “inflammaging,” which precedes many age-related diseases [12]. Considering the antiaging activity, a variety of synthetic and natural compounds has got keen interest in senolytic discovery (drugs selectively eliminating senescent cells) [13]. Fructus psoraleae is a traditional antiaging Chinese medical herb, and its resistance to “inflammaging” has become one of research concerns in antiaging field.

Psoralea prenyllavonoids have been shown to suppress Toll-like receptor- (TLR-) or IL-1β-induced inflammation response. Multiple reports indicated that isobavachalcone, bavachinin, and bavachin inhibit the expression of iNOS, COX-2, and mPGES-1 and the production of nitric oxide (NO) and prostaglandin E2 (PGE2) in microglia, macrophages, and chondrocytes [14–18]. Bavachin also inhibited IκBα degradation and increased the nuclear translocation of p65 and p50 proteins in the inflammatory chondrocytes and endothelial cells [19, 20]. In addition, bavachin significantly inhibited the activity and expression of matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motif (ADAMTS), while matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase (TIMPs) in mouse chondrocytes [17]. These findings showed that bavachin has an anti-inflammatory effect on chondrocytes and could be used to treat articular cartilage degeneration [17, 19]. Furthermore, bavachin has shown to attenuate LPS-induced inflammation and inhibit macrophage NLRP3 inflammasome activation. Bavachin suppressed caspase-1 activation, IL-1β secretion, and inflammasome complex formation [18]. Isobavachalcone can significantly downregulate the levels of intercellular adhesion molecule-1 (ICAM-1) and interferon-β (IFN-β) and inhibit leukocyte adhesion to endothelial cells through inhibiting the TLR4/MyD88 signaling pathway [20]. Studies have determined that neobavaisoflavone significantly inhibits the production of reactive oxygen species, reactive nitrogen species, and cytokines in LPS+IFN-γ- or PMA-stimulated RAW264.7 macrophages, such as IL-1β, IL-6, and tumor necrosis factor- (TNF-) α [21]. A previous study has shown that isobavachalcone, bavachin, bavachinin, and neobavaisoflavone also have inhibitory effects on IL-6-induced STAT3 promoter activity and phosphorylation in Hep3B cells [22].

Bavachinin attenuated HIF-1α activity under hypoxia in a concentration-dependent manner and reduced HIF-1α-regulated transcription of genes related to energy metabolism, such as glucose transporter type 1 (Glut1) and hexokinase 2 [23]. HIF-1α is the main oxygen sensor within cells and is essential to the regulation of cell responses to varying oxygen levels. The transcription factor HIF-1α forms a complex relationship with inflammation and mitochondrial metabolism [24–27]. Recent studies have elucidated a new mechanism for mitochondrial metabolism to promote IL-1β expression and activity via HIF-1α regulation [25, 28]. Activated PKM2 inhibited the LPS-induced expression of HIF-1α and IL-1β, as well as a series of other HIF-1α-dependent genes. PKM2 induced by LPS forms a complex with HIF-1α and directly binds to the IL-1β promoter. Researchers also observed that activated PKM2 inhibited LPS-induced glycolytic reprogramming and succinate production [28]. LPS-induced succinate stabilizes HIF-1α which leads to activation of the proinflammatory cytokine IL-1β [25]. In obesity-related heart failure with preserved ejection fraction (HFpEF), HIF-1α is responsible for recruiting M1 macrophages that mediate obesity-associated inflammation. M1 macrophages produce proinflammatory cytokines IL-6, monocyte chemoattractant protein-1 (MCP-1), TNF-α, and IL-1β and increase the expression of thrombospondin, pro α2 (I) collagen, transforming growth factor (TGF)-β, nitoaminde adenine dinucleotide phosphate (NADPH) oxidase, and connective tissue growth factor (CTGF) [29]. Therefore, the inhibition of HIF-1α activity by bavachinin antagonized the inflammatory response under ischemia and hypoxia (Figure 2).

Prenyllavonoids also induced the expression and activity of transcription factors. For example, isobavachalcone antagonized lung injury and myotube atrophy by increasing the activity and expression of nuclear factor erythroid 2-related factor 2 (Nrf2) [30, 31]. Nrf2 is highly sensitive to oxidative stress, which is closely related to inflammatory response [32] and aging-related diseases, cardiovascular diseases, Alzheimer’s and Parkinson’s diseases, and rheumatic diseases [33–38]. Researchers demonstrated that Nrf2 inhibition of ROS-induced NLRP3 priming required the participation of NAD(P)H quinone dehydrogenase 1 (NQO1) [39]. Furthermore, the inhibition of Nrf2 also regulated the NLRP3 inflammasome formulation, assembly-mediated cleaved caspase-1, and IL-1β secretion through the Trx1/TXNIP complex [40]. In addition, Nrf2 binding to antioxidant responsive element (ARE) site can trigger the transcription of more than 200 endogenous protective genes, such as antioxidiant, anti-inflammatory, and antiapoptotic genes [33, 41]. Therefore, the moderate expression and balance of Nrf2 promoted by prenyllavonoids are beneficial to the regulation of antioxidant, anti-inflammatory, and mitochondrial homeostasis (Figure 3).

Our latest study has shown that 4’-O-methybachachalcone significantly reduced cerebral infarction and edema, improved neurobehavioral indexes, inhibited the production of IL-1β, TNF-α, and IL-6 in ischemic brain, and reduced the level of NLRP3, cleaved caspase1, and GSDMD-N (gasdermin D N-terminal domain) in the mouse stroke model and in oxygen glucose deprivation- (OGD-) RAW264.7 cells [42]. Recently, gasdermin D and NLRP3 have been identified as programmed death patterns of stroke cell inflammation and pyrolysis [43]. Moreover, a specific pyroptosis inhibitor VX765 has a potential therapeutic value for cerebral ischemia by inhibiting the canonical inflammasome pathway of pyroptosis [44]. In brief, bavachalcone has the ability to inhibit the inflammatome NLRP3 activity and cell pyrolysis (Figure 3).

It has been reported that the bavachin activated gene expression of peroxisome proliferator-activated receptor
As we all know, PPARγ can transform proinflammatory cytokines produced by neutrophils, platelets, and macrophages into anti-inflammatory mediators. PPARγ and its ligands further regulate platelet and neutrophil function, reduce trafficking, promote neutrophil apoptosis, and prevent platelet-leukocyte interactions. PPARγ alters macrophage transport, increases efferocytosis and phagocytosis, and promotes macrophages to switch to M2-type polarity [46]. What is more, endothelial PPARγ is an indispensable factor to prevent endothelial dysfunction with aging [47], and interference with PPARγ function can accelerate vascular aging and atherosclerosis [48, 49]. Conversely, cell senescence may also alter the PPARγ-dependent fatty acid handling in human microvascular endothelial cells and contribute to inflammation [50].

In the following summary (Table 1), the cell or animal models, inflammation induction methods, active recipients, experimental doses, and pharmacological effects in more detail are provided. In general, prenylflavonoids inhibited JNK1/2, ERK1/2, NF-κB, STAT3, inflammatome NLRP3 activity, iNOS and mPGES-1 expression, secretion of many cytokines, and cell pyroptosis. These findings indicate that psoralea prenylflavonoids have the potential effects on improving “inflammaging” environment and aging-related diseases.

3. Cardiovascular Function Regulation

The age-related status changes lead to low-degree inflammation and increase of oxidative stress in the cardiovascular system. The phenotypes of these changes include rigidity of
Table 1: Summary of anti-inflammation experiments of five psoralea prenylflavonoids.

| Cells or animals | Model method | Active ingredient | Dosage | Pharmacological effect | Reference number |
|------------------|--------------|------------------|--------|------------------------|-----------------|
| BV-2 microglia   | LPS          | Isobavachalcone  | 2, 5, 10 μmol/L | (i) Concentration-dependent inhibitory effects on NO and PGE₂ production with an IC₅₀ for inhibiting NO production: 1.6 ± 0.11 μmol/L (ii) Blocked the I-κB degradation and downregulated NF-κB activity (iii) Inhibited the iNOS and COX-2 mRNA and protein expression | [14] |
| RAW264.7 murine monocytic cells | MALP-2; LPS Poly[1-C] | Isobavachalcone          | 20, 50, 100 μmol/L | (i) Concentration-dependent inhibitory effects on NO production with an IC₅₀: 26 μmol/L (bavachinin), 17 μmol/L (isobavachalcone), 29 μmol/L (neobavaisoflavone) | [15] |
| Microglial cells | LPS          | Bavachinin Isobavachalcone Neobavaisoflavone | 1, 3, 10, 30, 100 μmol/L | (i) Downregulated ICAM-1 mRNA and protein expression (ii) Suppressed NF-κB activity (iii) Dose-dependently attenuated the adhesion of monocytes to endothelial cells activated by LPS | [20] |
| bEnd.3 murine brain endothelial cells | MALP-2; LPS Poly[1-C] | Isobavachalcone          | 0.1, 1, 5 μmol/L | (i) Upregulated aggrecan and collagen type II expression in a dose-dependent manner (ii) Inhibited MMP-1/3/13, and ADMATS-4/5 expression, and upregulated TIMP-1/2/3/4 expression (iii) Inhibited iNOS and COX-2 expression and downregulated NO and PGE₂ in a dose-dependent manner | [19] |
| Primary rat chondrocytes | Non | Bavachin          | 5, 10 μmol/L | (i) Inhibited iNOS and mPGES-1 expression and downregulated NO and PGE₂ in a dose-dependent manner (ii) Inhibited phosphorylation of JNK 1/2 and ERK 1/2, and downregulated NF-κB activity (iii) Suppressed production of IL-β and the expression of NLRP3 inflammasome complex (iv) Inhibited production of NO, IL-6 and IL-12p40 in LPS-stimulated murine peritoneal macrophages | [17] |
| Murine J774A.1 cells and murine peritoneal macrophages | LPS | Bavachin          | 10, 20, 30, 40 μmol/L | (i) Inhibited iNOS and mPGES-1 expression and downregulated NO and PGE₂ in a dose-dependent manner (ii) Inhibited phosphorylation of JNK 1/2 and ERK 1/2, and downregulated NF-κB activity (iii) Suppressed production of IL-β and the expression of NLRP3 inflammasome complex (iv) Inhibited production of NO, IL-6 and IL-12p40 in LPS-stimulated murine peritoneal macrophages | [18] |
| RAW264.7 macrophages | LPS + IFN-γ | Neobavaisoflavone | 2.5, 5, 10, 25, 50 μmol/L | (i) Inhibited the production of ROS, RNS, and cytokines: IL-1β, IL-6, IL-12p40, IL-12p70, and TNF-α with ED₅₀ 25.00 μmol/L (NO); 23.11 μmol/L (IL-1β); 5.03 μmol/L (IL-6); 5.23 μmol/L (IL-12p40); 5.26 μmol/L (IL-12p70); 18.80 μmol/L (TNF-α) | [21] |
| Hep3B cells | IL-6 | Bavachinin Isobavachalcone Neobavaisoflavone | 10, 30, 60 μmol/L | (i) Inhibited STAT3 phosphorylation with an IC₅₀ for STAT3-dependent promoter activity: 4.89 ± 0.05 μmol/L (bavachinin), 3.02 ± 0.53 μmol/L (isobavachalcone), 2.45 ± 0.13 μmol/L (neobavaisoflavone) | [22] |
elastic arteries, endothelial dysfunction, hypoperfusion cerebral ischemia, stroke, and cardiac diastolic dysfunction. This involves the Klotho longevity gene, the AMPK energy-sensitive pathway, and the activity and expression of eNOS, MnSOD, and PGC-1α genes.

The cardiovascular protective effects of prenylflavonoid derivatives from fructus psoraleae have been reported (Table 2). Kassaun et al. [51] reported that isobavachalcone inhibited hTRPC3 current, which significantly relaxes the contraction of the endothelium-intact aortic rings induced by phenylephrine. In addition, a previous study has shown that isobavachalcone inhibits platelet aggregation induced by arachidonic acid, collagen, and platelet activating factor in rabbits [52]. As we all know, platelet aggregation is closely related to myocardial infarction and stroke [53, 54].

Acyl-CoA:cholesterol acyltransferase (ACAT), a key enzyme regulating cholesterol esterification, induced the accumulation of cholesterol esters in the endoplasmic reticulum of macrophages and smooth muscle cells and promoted the formation of foam cells [55, 56]. However, the enzyme was inhibited by isobavachalcone and bavachin in an ACAT noncompetitive inhibition type [7]. In in vitro studies performed by our team in human endothelial cells, bavachalcone suppressed cell senescence by decreasing the activity of a senescence-associated β-galactosidase (a senescent marker) and downregulating mRNA expression of p16 (ink4a) (a marker of replicative senescence) and IL-1α (a proinflammatory cytokine of SASP) [57]. Bavachalcone also activated retinoid-related orphan receptor alpha 1 (RORa1) reporter gene activity and induced RORα1 mRNA expression in a dose-dependent manner, resulting in the enhancement of the amplitude of circadian rhythm of Bmal1 mRNA expression after serum shock [57]. Another study has shown that bavachalcone protected endothelial cells by increasing the activity of adenosine 5'-monophosphate-activated protein kinase (AMPK) and the expression of manganese-superoxide dismutase (MnSOD) and PGC-1α, inhibiting mitochondrial oxidative stress and improving mitochondrial biogenesis [58]. We also have found that bavachalcone promoted endothelial progenitor cell (EPC) differentiation and neovascularization through the AMPK pathway. Oral administration of bavachalcone for 14 days stimulated neovascularization and reestablishment of microcirculation in a rat ischemic hind limb model. The number of EPCs and the level of erythropoietin (EPO) in the circulation were increased in rats with bavachalcone treatment. Furthermore, bavachalcone enhanced the activity of RORα1 and EPO reporter genes [59]. Bahlmann et al. [60] reported that the treatment of recombinant human EPO caused a significant mobilization of circulating CD34(+)/CD45(+) EPC in the peripheral blood and increased the number of functionally active EPCs in patients and healthy subjects. Previous clinical studies and animal experiments also have shown that EPO therapy increased the number of circulating EPCs and promoted homing and improved acute myocardial infarction, heart failure, stroke, and cerebral aneurysm [61–64]. Our multiple results indicate (Figure 4) that AMPK-mediated cardiovascular protection of bavachalcone can include regulating mitochondrial biogenesis [65], delaying cell senescence [66], activating ENOS, MnSOD and PGC-1α activity and expression [67, 68], and promoting EPC differentiation [69], which presents consistency with the results of other research groups.

### 4. Diabetes and Obese Intervention

Aging, diabetes, and obesity had a synergistic effect on inflammation and oxidative stress among the elderly, which in turn increased the risk of diabetes and obesity. Early interventions to reduce inflammation, oxidative stress, and insulin resistance may improve age-related diseases [70–73]. Fructus psoraleae, as an option for seeking treatment and prevention of diabetes and obesity, has the potential to improve the active life expectancy of the elderly.

A recent report revealed that psoralea prenylflavonoid extract (PFE) significantly reduced body weight and fat mass in a dose-dependent manner, increased energy expenditure, improved insulin sensitivity, and prevented hepatic steatosis by increasing lipid oxidation and secretion in high-fat diet-fed mice. The study also found that PFE induced clear browning in subcutaneous white adipose tissue, increased brown adipose tissue activity, and thermogenic genes [74]. Another research group also reported that the extract of Psoralea corylifolia seeds attenuated methylglyoxal-induced insulin resistance and significantly increased the phosphorylation of Akt, IRS-1/2, and glucose uptake [75]. Moreover, this extract reduced nonalcoholic fatty liver disease, the expression of lipogenic, and inflammatory genes, such as TNF-α, IL-1β, and iNOS in high-fat diet-induced obese mice [76]. In addition, Lee et al. [45] showed that bavachin (2 μM) increased the expression and secretion of adiponectin and

| Cells or animals | Model method | Active ingredient | Dosage | Pharmacological effect | Reference number |
|-----------------|--------------|-------------------|--------|------------------------|-----------------|
| Male ICR mice   | Ischemic stroke | 4‘-O- methylvachalcone | 5, 10, 20 mg/kg, oral gavage after animal modeling, daily | (i) Improved the area of cerebral infarction, brain edema, and neurobehavioral indexes 48 hours after MCAO/R |
|                 |              |                    | (ii) Lowered active-PARP and cleaved-caspase-3 levels | (iii) Inhibited IL-1β, TNF-α, and IL-6 production in ischemic cerebral homogenate |
|                 |              |                    | (iv) Reduced NLRP3/GSDMD-mediated pyroptosis of brain tissue and cells | |

**Table 1: Continued.**
Table 2: Experimental summary of five psoralea prenylflavonoids improving aging-related diseases.

| Classification            | Model                                      | Stimulation                                                                 | Active ingredient               | Dosage                  | Pharmacological effect                                                                 | Reference number |
|---------------------------|--------------------------------------------|------------------------------------------------------------------------------|---------------------------------|-------------------------|----------------------------------------------------------------------------------------|------------------|
| Cardiovascular function   | Male SD rat aortic rings and HEK293 cells  | Exposure to 60 μmol/L KCl followed by two exposures to 1 μmol/L phenylephrine| Isobavachalcone                | 50 μmol/L for aortic rings and 150 μmol/L for hTRPC3 test | (i) Caused the relaxation of precontracted aortic rings in the presence of endothelium (ii) Isobavachalcone-induced vasodilation was blocked by NOS inhibitor L-NAME and SGC blocker ODQ (iii) Inhibited hTRPC3 currents (27.1 ± 7.9%) | [51]             |
|                           |                                            |                                                                              |                                 |                         | (i) Concentration-dependent inhibition of platelet aggregation (ii) IC₅₀ for isobavachalcone: 65.1 ± 9.1 μmol/L (col), 0.5 ± 0.1 μmol/L (AA), and 41.6 ± 6.2 μmol/L (PAF); IC₅₀ for neobavaisoflavone: 62.4 ± 10.4 μmol/L (col), 7.8 ± 2.5 μmol/L (AA), and 2.5 ± 0.3 μmol/L (PAF) (i) Inhibits ACAT activity (ii) IC₅₀ values were 86.0 μmol/L (bavachin) and 48.0 μmol/L (isobavachalcone) in the ACAT assay system (iii) Isobavachalcone inhibited cholesteryl ester formation in a dose-dependent fashion with an IC₅₀ value of 100.2 μmol/L in HepG2 cells (i) Inhibited acidic beta-galactosidase activity (ii) Induced RORα expression in RORα reporter luciferase activity, mRNA, and protein levels in a dose-dependent manner and enhanced the circadian amplitude of Bmal1 mRNA expression after serum shock (iii) Suppressed senescence in human endothelial cells and mRNA expression of p16 (ink4a) (a marker of replicative senescence) and IL-1α (a proinflammatory cytokine of the senescence- | [52]             |
|                           |                                            |                                                                              |                                 |                         |                                                                                        | [7]              |
|                           | Platelets from fresh rabbit blood          | Induction with collagen (col), arachidonic acid (AA), or platelet-activating-factor (PAF) | Isobavachalcone Neobavaisoflavone | 2, 5 or 80 nmol/L |                                                                                        |                  |
|                           |                                            |                                                                              |                                 |                         |                                                                                        |                  |
|                           | Rat liver microsome And HepG2 cells        | Non                                                                          | Bavachin Isobavachalcone        | 3.0, 9.3, 30, and 8, 93.0, 300 μmol/L | (i) Inhibited acidic beta-galactosidase activity (ii) Induced RORα expression in RORα reporter luciferase activity, mRNA, and protein levels in a dose-dependent manner and enhanced the circadian amplitude of Bmal1 mRNA expression after serum shock (iii) Suppressed senescence in human endothelial cells and mRNA expression of p16 (ink4a) (a marker of replicative senescence) and IL-1α (a proinflammatory cytokine of the senescence- |                  |
|                           |                                            |                                                                              |                                 |                         |                                                                                        | [57]             |
| Classification | Model | Stimulation | Active ingredient | Dosage | Pharmacological effect | Reference number |
|----------------|-------|-------------|-------------------|--------|------------------------|------------------|
| HUVEC          |       | Induction of senescent cells by hydrogen peroxide | Bavachalcone | 1, 2, 5 μmol/L | (i) Inhibited acidic beta-galactosidase activity (ii) Promoter and increased MnSOD mRNA and protein expressions (iii) Suppressed the mitochondrial superoxide production in endothelial cells (iv) Stimulated liver kinase B1 and AMPKα phosphorylation (v) AMPK knockdown by shRNA-AMPK reversed the effects of bavachalcone on MnSOD | [58] |
| (1) HUVECs     |       |             |                   |        |                        |                  |
| (2) EA.hy926   |       |             |                   |        |                        |                  |
| (3) Rat bone   |       |             |                   |        |                        |                  |
| marrow mesenchymal cells | |             |                   |        |                        |                  |
| (4) Male       |       |             |                   |        |                        |                  |
| Wistar rat     |       |             |                   |        |                        |                  |
| Diabetes and   | Mouse 3T3-L1 | Media containing MDI (1 μg/mL isobutylmethylxanthine, 1 μM dexamethasone, and 1 μg/mL insulin) | Bavachin | 2 μmol/L | (i) Increased the expression and secretion of adiponectin (ii) Enhanced glucose uptake via GLUT4 translocation (i) Bavachinin dose-dependently induced the transcriptional activities of | [45] |
| obese          | preadipocytes | | | | | |
| intervention   | | | | | | |
| 9-week-old     | High-fat diet | | | 50 and 100 mg/kg/day | | [80] |
| female db/db   |       |             |                   |        |                        |                  |
| mice           |       |             |                   |        |                        |                  |
| Classification | Model | Stimulation | Active ingredient | Dosage | Pharmacological effect | Reference number |
|----------------|-------|-------------|-------------------|--------|------------------------|------------------|
| 3T3-L1 preadipocytes and Zebrafish | Media containing MDI (1 μg/mL isobutyl-methylxanthine, 1 μM dexamethasone, and 1 μg/mL insulin) | Isobavachalcone  | 2, 10, 40 μmol/L | the mouse ligand-binding domain of PPARγ and PPARα  
(ii) Ameliorates diabetes and hyperlipidaemia in db/db and in diet-induced obese mice  
(iii) Decreased lipid accumulation in liver in db/db and in diet-induced obese mice  
(iv) Regulates PPAR gene expression in vitro and in vivo  
(v) Occupies a novel alternative binding site in addition to the canonical site of synthetic agonists of PPARγ | [81] |
| BV-2 microglia | LPS 450 μmol/L of H2O2 solution | Bavachalcone, Bavachinin, Isobavachalcone | 1, 10, 100 μmol/L | (i) Decreased protein levels of PPARγ and C/EBPα  
(ii) Gene expression levels of SREBP1c, adiponectin, ACC1, and FAS  
(iii) Inhibited adipogenesis and prevents lipid accumulation in high cholesterol-diet Zebrafish larvae | [82] |
| Neuroprotection | SH-SY5Y cell line  
Yeast two hybrid | Aβ42  
Isobavachalcone (IBC)  
Bavachinin (BCN) | 3 μmol/L (IBC) and 30 μmol/L (BCN) | (i) Inhibited Aβ42 aggregation  
(ii) Attenuated Aβ42-induced cell toxicity  
(i) Improved the motor, balance, and coordination abilities of PD mouse  
(ii) Inhibited the activation of microglia and astrocytes and the necrosis of neurons injured by MPTP  
(iii) Decreased the levels of IL-6 and IL-1β in PD mouse and of TNF-α, IL-6, | [83] |
| Mouse BV-2 cells  
Neuro-2a cells  
Male C57BL/6 mice | LPS  
Preadministration of MPTP (20 mg/kg) | Isobavachalcone | 0.1, 1, 5, 10, 20 μmol/L, 50 mg/kg | | [84] |
| Classification                          | Model                      | Stimulation                      | Active ingredient          | Dosage                  | Pharmacological effect                                                                 | Reference number |
|----------------------------------------|----------------------------|----------------------------------|---------------------------|------------------------|----------------------------------------------------------------------------------------|------------------|
| BV-2 cells                             | LPS (1 μg/mL)              | Neobavaisoflavone                | IL-1β, and IL-10 in BV-2 cells stimulated by LPS          | (iv) Inhibited the activation of p65 subunit in brain tissues the expression of p65 in BV-2 cells (v) Inhibited the levels of NO and the expression of iNOS in LPS-treated BV-2 cells | [85] |
| HT22 hippocampal cells                 | 250 μmol/L of H2O2         |                                   |                          |                        | (i) Protective effects against H2O2-induced neuronal cell damage in HT22 hippocampal cells (ii) Isobavachalcone had the most significant inhibitory effect on the LPS-induced NO production in dose-dependent manners in BV-2 cells |                  |
| Human hMAO-A and hMAO-B                | Non Bavachinin             | 10, 20, and 40 μmol/L or 18.75, 75, and 300 μmol/L | (i) Selectively inhibited MAO-A and MAO-B activity (ii) With IC50 of 8.82 μmol/L (hMAO-B) and 189.28 μmol/L (hMAO-A) (iii) Bavachinin C7-methoxy group had higher affinity for hMAO-B using molecular docking examination | [86] |
| HeLa cells                             | Non Bavachalcone           | 10⁻⁹, 10⁻⁸, 10⁻⁷, 10⁻⁶ mol/L     | (i) Activated transcription of ERα or ERβ in HeLa cells (i) Increased the thickness and integrality of femur cortical bone (ii) Increased the mRNA level of OPG in the OVX femur (iii) Promoted the proliferation of human osteoblasts (iv) Induced primary human osteoblast differentiation by upregulated the Wnt3a/β-catenin signaling pathway (v) Increased ALP, Runx2, OCN, Col-I, and LRP5 expression | [126] |
| Regulation of bone formation and absorption | Female SD rats Ovariectomy | Bavachin                         | 8 mg/kg/day 0.5, 5, 50 μmol/L |                        | (i) Induced mineralization in MC3T3-E1 cells                                             | [127] |
|                                        | Human osteoblasts          | Neobavaisoflavone                |                           |                        |                                                                                        |                  |
|                                        | MC3T3-E1 cells             | Non Neobavaisoflavone            | 1, 5, 10, 15, 20 μmol/L |                        |                                                                                        | [130] |
enhanced glucose uptake via GLUT4 translocation by activating the protein kinase B (Akt) and AMPK pathway in the presence or absence of insulin. Targeting the AMPK signaling pathway is one of the target pathways to control diabetes. Some studies have shown that diabetic patients have impaired AMPK activity, and metformin, which is used to treat diabetes, works by regulating AMPK. Natural medicines of plant origin showed great potential in regulating and activating the AMPK pathway and can be used as drug candidates for the treatment of diabetes and its complications [77, 78].

Moreover, bavachin promoted lipid accumulation in 3T3-L1 cells at differentiation day 8 by activating gene expression of peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT/enhancer binding protein alpha (C/EBPα) [45], suggesting that bavachin might have therapeutic potential for type 2 diabetes. Like bavachin, bavachinin is a PPARγ agonist. Isolated bavachinin is a mixture of S and R configurations. A time-resolved fluorescence resonance energy transfer-based competitive binding assay showed that (S)- and (R)-bavachinin had similar PPARγ

Table 2: Continued.

| Classification | Model | Stimulation | Active ingredient | Dosage | Pharmacological effect | Reference number |
|---------------|-------|-------------|------------------|--------|------------------------|------------------|
| Bone marrow-derived macrophages | RANKL | Vitamin D3 (10^-6 mol/L) and PGE2 (10^-8 2mol/L). | Bavachalcone | 0.5, 1, 2, 5 μmol/L | (ii) Upregulated the expression of Runx2 and Osx (i) Induced activation of ALP, the expression of Col-I, OCN, and BSP (i) Inhibited osteoclastogenesis in coculture of whole bone marrow cells and calvarial osteoblasts and inhibited bone resorption (ii) With the IC_{50} of approximately 1.5 μmol/L (iii) Suppressed the expression of c-Fos and NFATc1 by RANKL (iv) Reduced activation of MEK, ERK, and Akt by RANKL | [135] |

Figure 4: The schematic diagram of bavachalcone improving cardiovascular function by activating AMPK and promoting EPO expression.
agonist activities with IC_{50} 616.7 nM and 471.2 nM, respectively [79]. Subsequent in vivo studies have shown that bavachinin exhibited blood glucose-lowering properties without causing weight gain and liver toxicity. Importantly, bavachinin had synergistic effects with the synthetic PPARγ agonist thiazolidinediones and PPARα agonist fibrates, which induced PPAR transcriptional activity, as well as lowered glucose and triacylglycerol levels in db/db mice [80]. Further research found that bavachinin bound not only to the canonical site of PPAR agonists but also to a novel alternative binding site. Moreover, resiglitazone pretreatment prevented bavachinin from binding to the canonical site instead of a novel alternative binding site [80]. The sketch of bavachinin activating PPARs to improve insulin resistance and obesity is shown in Figure 5.

Isobavachalcone caused 3T3-L1 cell cycle arrest at G0/G1 and dose-dependently inhibited the protein expression levels of cyclin D1, cdk4, and cdc6 within 48 h after adipocyte differentiation medium MDI stimulation. Moreover, while isobavachalcone inhibited adipocyte fat accumulation, it also reduced intrahepatic fat deposition and hepatic steatosis in zebrafish fed high fat cholesterol diets [81]. Table 2 summarizes the experimental data related to diabetes and obesity.

5. Neuroprotection

Aging is the most important independent risk factor for neurodegenerative diseases. Millions of people suffer from Alzheimer’s disease (AD), Parkinson’s disease (PD), vascular dementia (VD), and ischemic stroke around the world. Fructus psoraleae is a promising antiaging Chinese herb which is introduced for the therapy of neurodegenerative diseases. Several studies have demonstrated that Psoralea corylifolia seed extracts can exert neuroprotection in vivo and in vitro. Alzheimer’s disease (AD) is an age-related neurodegenerative disease. Evidence showed that four components of Psoralea corylifolia, named bavachinin, bavachalcone, and isobavachalcone, differentially inhibited neuroinflammation, oxidative damage, and key AD-related protein targets, such as amyloid β-peptide 42, β-secretase, glycogen synthase kinase 3β, and acetylcholinesterase in vivo [82]. The researchers further revealed that isobavachalcone and bavachinin regulate the aggregation of Aβ42 through different mechanisms. Isobavachalcone significantly inhibited both oligomerization and fibrillization of Aβ42, whereas bavachinin inhibited fibrillization and led to off-pathway aggregation. Both of the compounds attenuated Aβ42-induced toxicity in an SH-SY5Y cell model [83]. Meanwhile, isobavachalcone can also effectively relieve Parkinson’s disease (PD) induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), prolong the residence time of mice on Rota-rod, and alleviate the neuronal necrosis [84]. Isobavachalcone also inhibited the activation of microglia and decreased the expression of IL-6 and IL-1β in the brain of PD mice [80]. In vitro, isobavachalcone significantly suppressed BV-2 microglia activation and the NO production induced by LPS [84], while neobavaisoflavone had a strong inhibitory activity on H2O2-induced cell death in HT22 hippocampal cells [85]. Monoamine oxidase B (MAO-B) is an enzyme that breaks down dopamine in the brain. MAO-B inhibitors block the action of the enzyme and therefore improve the symptoms in early PD. A molecular docking test found that the C7 methoxy group of bavachinin has a high affinity for MAO-B, suggesting that bavachinin might be a selective and competitive human MAO-B inhibitor and could be used in the PD treatment [86]. The experimental details are summarized in Table 2.

Recently, bavachinin was identified as a novel agonist that activates all three PPAR isoforms, so-called pan-PPAR agonist [80], which indicated its potentially powerful application of prenylflavonoids in neuroprotection. PPARγ agonists have been demonstrated as neuroprotective agents. Pioglitazone and 15d-prostaglandin J2 significantly reduced the infarct volume, attenuated the aggregation of parenchymal neutrophils, decreased the release of TNF-α, IL-1β, and IL-6, and improved neurological function in the cerebral ischemia injury mice [87, 88]; reduced β-amyloid levels effectively reversed cerebrovascular damage, improved energy metabolism and antioxidant capacity of model mice’s cortex, and inhibited β-amyloid-stimulated COX-2, TNF-α, and IL-6 expression in Alzheimer’s disease models [89–91]. Pioglitazone and MDG548 also increased the phagocytosis of microglia on necrotic cells, reduced the death of dopaminergic neurons and the production of cellular reactive oxygen species, upregulated the expression of MRC1, CD68, and IL-10, elevated the activity of glutathione-S-transferase, and blocked the activity of monoamine oxygenase B in the Parkinson’s disease model MPTP-mice [92–94].

Endogenous Nrf2 is the main regulator of the antioxidant response and an indicator of oxidative stress. Numerous research data indicated that Nrf2 mediated the neuroprotective effect of active ingredients of Chinese herbal medicine on Parkinson’s disease [95, 96], Alzheimer’s disease [97, 98], vascular dementia [99, 100], and cerebral ischemia-reperfusion injury [101–103]. In vivo and in vitro studies suggested that isobavachalcone may act as a potential neuroprotective agent by increasing Nrf2 activity and expression [30, 31]. The therapeutic potential of EPO in brain plays a neuroprotective role against Alzheimer’s disease [104, 105], Parkinson’s disease [106–108], chronic cerebral hypoperfusion-induced vascular dementia [109, 110], and cerebral ischemia-reperfusion injury [111–113]. The elevation of expression and circulating concentration of EPO improved the therapeutic effects of bavachalcone and other flavonoids of Chinese herbal medicine in brain diseases [59, 114–116]. The neuroprotective effects of psoralea prenylflavonoids are summarized in Figure 6.

6. Improve Osteoporosis

Senile osteoporosis is caused by aging and affects both men and women. The evidences showed that (1) senescence of bone marrow stromal cells (BMSCs) was more likely to differentiate into adipocytes rather than osteoblasts [117, 118]; (2) age-dependent bone loss is associated with increased bone cell DNA damage, cell aging, SASP, and elevated RANKL levels [119–121]; and (3) excessive osteoclast activity induced by aging is closely related to inflammation, which
induced osteoporosis, while anti-inflammatory drugs inhibit osteoclast formation and bone resorption [122–124].

In China, fructus psoraleae is often used to treat fractures, osteomalacia, and osteoporosis. A phytoestrogen effect was considered to play an important role in studies on the material basis of fructus psoraleae and its pharmacological action (Table 2). Xin and colleagues [125] found that bavachin, isobavachalcone, and neobavaisoflavone activate estrogen receptor ERα and ERβ, while pure estrogen antagonists ICI-182,780 completely block the activation of estrogen receptors. Bavachin, isobavachalcone, and neobavaisoflavone also significantly promoted osteoblast proliferation [126]. In a model of bone loss caused by ovariectomy, in vivo experiments showed that bavachin prevents bone loss by up-regulating the Wnt signaling pathway [127]. Wnt/β-catenin signaling pathway regulated cell fate and promoted BMSCs transfer to osteoblasts rather than adipocytes [128, 129]. Neobavaisoflavone stimulated osteogenesis of MC3T3-E1 osteoblasts in a dose-dependent manner, which is manifested by notable enhancement of ALP activity, significantly increased bone-specific matrix proteins including type I collagen (Col-I), osteocalcin (OCN), and bone sialoprotein (BSP) and formation of bone nodules. Neobavaisoflavone also upregulated the mRNA expression of transcription factors Runx2 and Osterix (Osx) through a p38-dependent signaling pathway then exerted osteogenic activity [130].
Runx2, ALP, and OCN are integral factors for the control of osteogenesis. Many research reported that Runx2 can promote osteogenic differentiation and inhibit fat differentiation [131, 132]. As an osteoblast-specific transcription factor, Osx is also required for osteoblast differentiation. Osx showed a transcriptional regulatory mechanism for BSP gene expression, which is related to osteoblast differentiation and the onset of mineralization [133]. Interestingly, aiming at 162 potential bone-promoting target proteins, Ge et al. [134] revealed that 8 ingredients of 23 known psoralen components, such as bavachalcone, bavachinin, and neobavaisoflavone, may be the main activities of psoralea-promoting bone formation in MC3T3-E1 cells. In summary, psoralea prenylflavonoids promoted bone formation in many ways (Figure 7).

Contrary to osteoblasts, osteoclast is a kind of cell that has a special effect on bone absorption. Disorder of bone absorption is the main culprit of many bone diseases such as osteoporosis. Bavachalcone inhibited the differentiation of precursor cells into osteoclasts by interfering with the extracellular regulated protein kinases (ERK) and Akt pathways and suppressed the expression of c-Fos and NFATc1 via receptor activator of nuclear factor κB ligand (RANKL) [135]. NFATc1 induced by the cytokine RANKL is a major regulator of the osteoclast transcriptome. NFATc1 promoted the expression of many genes, such as Itgb3, Oscar, Acp5, and Ctsk promoters, which were required for osteoclastogenesis and bone resorption [136]. NFATc1 protein expression and transcriptional activity also played important roles in inflammatory osteoclastogenesis and pathological bone loss [137, 138]. An earlier study reported that bavachalcone can intervene with osteoclastogenesis by inhibiting the induction of c-Fos and NFATc1 [135]. AMPK, a negative regulator of
NFATc1 activation, antagonized osteoclastogenesis [139, 140]. Estrogen and phytoestrogens also negatively regulated the RANKL-induced osteoclastic differentiation [141–143]. Many studies revealed that psoralea prenylflavonoids activate the AMPK pathway and present estrogen-like effects, which explained their inhibitory mechanism on osteoclastogenesis (Figure 8).

In conclusion, this article summarizes the numerous pharmacological effects of psoralea prenylflavonoids on aging-related diseases, including anti-inflammatory action, cardiovascular protection, diabetes and obese intervention, neurodegenerative diseases improvement, and osteoporosis alleviation. This article also discusses the regulation of these active ingredients on the key pathways, such as AMPK, EPO, HIF-1α, NFATc1, NF-κB, Nrf2, Osx, PPARγ, Runx2, and Wnt/β-catenin, as well as inflammatome NLRP3. However, there is insufficient evidence to prove that these five psoralea prenylflavonoids can be used as senolytics (eliminating senescent cells) or as senomorphics (modifying SASP components) drugs and can only be considered to prevent certain aging-related signaling pathways by entering cells. The summary and discussion of these pharmacological effects and regulatory mechanisms of psoralea prenylflavonoids will help to improve the recognition of the material basis of the pharmaceutical function of fructus psoraleae and will have a positive significance for the interpretation of its pharmacological effect.

**Abbreviations**

Aβ42: A 42 amino acid proteolytic product from the amyloid precursor protein  
ACAT: Acyl-CoA:cholesterol acyltransferase  
AD: Alzheimer’s disease  
ADAMTS: A disintegrin and metalloproteinase with thrombospondin motif  
Akt: Protein kinase B  
ALP: Alkaline phosphatase  
AMPK: Adenosine 5’-monophosphate-activated protein kinase  
ARE: Antioxidant responsive element  
BSP: Bone sialoprotein  
C/EBPα: CCAAT/enhancer binding protein alpha  
Col-I: Type I collagen  
COX-2: Cyclooxygenase-2  
CTGF: Connective tissue growth factor  
EPCs: Endothelial progenitor cells  
EPO: Erythropoietin  
ERK: Extracellular regulated protein kinases  
GLUT: Glucose transport protein  
HIF-1α: Hypoxia-inducible factor 1alpha  
hTRPC3: Human transient receptor potential cation channel subfamily C member 3  
ICAM-1: Intercellular adhesion molecule-1  
IFN-β: Interferon beta  
IL-1α: Interleukin 1 alpha  
iNOS: Inducible nitric oxide  
IκBα: NFκB inhibitor alpha  
LPS: Lipopolysaccharide  
MAO-B: Monoamine oxidase B  
MCP-1: Monocyte chemoattractant protein-1  
Medium MDM: Medium with M-CSF/dexamethasone/IL-4  
MMPs: Matrix metalloproteinases  
MnSOD: Manganese-superoxide dismutase  
MRC1: Mannose receptor C-type 1  
mPGES-1: Prostaglandin E synthase-1  
MPTP: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine  
MyD88: MYD88 innate immune signal transduction adaptor  
NADPH: Nicotinamide adenine dinucleotide phosphate  
NFATc1: Nuclear factor of activated T cells 1  
NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells  
NLRP3: NOD-, LRR-, and pyrin domain-containing protein 3  
NO: Nitric oxide  
Nrf2: Nuclear factor erythroid 2-related factor 2  
OCN: Osteocalcin  
PD: Parkinson’s disease  
PGE₂: Prostaglandin E2  
PKM2: Pyruvate kinase M2  
PPARγ: Peroxisome proliferator-activated receptor gamma  
RANKL: Receptor activator of nuclear factor κB ligand  
RORa1: Retinoid-related orphan receptor alpha1  
STAT3: Signal transducer and activator of transcription 3  
TGF-β: Transforming growth factor beta  
TLR4: Toll-like receptor 4  TNF-α: Tumor necrosis factor alpha  
Trx1: Thioredoxin  
TXNIP: Thioredoxin interacting protein  
VEGF: Vascular endothelial growth factor  
VHL: von Hippel-Lindau.

**Conflicts of Interest**

The authors declare that they have no competing interests.

**Authors’ Contributions**

Yi-Ting Zhou and Lin Zhu contributed equally to this work.

**Acknowledgments**

This work was supported by grants from the Specialized Research Fund for the National Natural Science Foundation of China (81274130 and 81973511).

**References**

[1] T. T. Yang and M. J. Qin, "Isolation and structure identification of a new isolavone from Psoralea corylifolias," Acta pharmaceutica Sinica, vol. 41, no. 1, pp. 76–79, 2006.
[2] R. P. Yang, Q. Y. Shou, X. M. Zhang, B. H. Wang, and N. Li, “Chemical composition analysis of ethyl acetate extract active fractions from Psoralea corylifolia (Article in Chinese),” Chong Qing Zhong Cao Yao Yan Jiu, vol. 64, no. 2, pp. 13–15, 2011.

[3] Y. F. Yang, Y. B. Zhang, Z. J. Chen, Y. T. Zhang, and X. W. Yang, “Plasma pharmacokinetics and cerebral nuclei distribution of major constituents of Psoraleae fructus in rats after oral administration,” Phytomedicine, vol. 38, no. 38, pp. 166–174, 2018.

[4] D. Zhou, L. An, Y. Xia, Y. Wang, and X. Li, “Quantitative bioanalysis of bavachalcone in rat plasma by LC–MS/MS and its application in a pharmacokinetics study,” Biomedical Chromatography, vol. 31, no. 12, article e4031, 2017.

[5] Z. J. Li, A. Abulizi, G. L. Zhao et al., “Bakuchiol Contributes to the Hepatotoxicity of Psoralea corylifolia in Rats,” Phytotherapy Research, vol. 31, no. 8, pp. 1265–1272, 2017.

[6] Y. Wang, H. Zhang, J. M. Jiang et al., “Hepatotoxicity induced by psoralen and isoposoralen from Fructus Psoraleae: Wistar rats are more vulnerable than ICR mice,” Food and Chemical Toxicology, vol. 125, pp. 133–140, 2019.

[7] J. H. Choi, M. C. Rho, S. W. Lee et al., “Bavachin and isobavachalcone, acyl-coenzyme A: Cholesterol acyltransferase inhibitors from Psoralea corylifolia,” Archives of Pharmacal Research, vol. 31, no. 11, pp. 1419–1423, 2008.

[8] Y. G. Li, J. Hou, S. Y. Li et al., “Fructus Psoraleae contains natural compounds with potent inhibitory effects towards human carboxylesterase 2,” Fitoterapia, vol. 101, pp. 99–106, 2015.

[9] L. Shan, S. Yang, G. Zhang et al., “Comparison of the Inhibitory Potential of Bavachalcone and Corylin against UDP-Glucuronosyltransferases,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 958937, 6 pages, 2014.

[10] X. X. Wang, X. Lv, S. Y. Li et al., “Identification and characterization of naturally occurring inhibitors against UDP-glucuronosyltransferase 1A1 in Fructus Psoraleae (Bu-gu-zhi),” Toxicology and Applied Pharmacology, vol. 289, no. 1, pp. 70–78, 2015.

[11] M. Shi, Y. Cui, C. Liu, C. Li, Z. Liu, and W.-y. Kang, “CYPs-mediated drug-drug interactions on psoralidin, isobavachalcone, neobavaisoflavone and daidzein in rats liver microsomes,” Food and Chemical Toxicology, vol. 136, article 111027, 2020.

[12] F. Olivieri, F. Prattichizzo, J. Grillari, and C. R. Balistreri, “Cellular senescence and inflammaging in age-related diseases,” Mediators of Inflammation, vol. 2018, Article ID 9076485, 6 pages, 2018.

[13] F. Gurău, S. Baldoni, F. Prattichizzo et al., “Anti-senescence compounds: a potential nutraceutical approach to healthy aging,” Ageing Research Reviews, vol. 46, pp. 14–31, 2018.

[14] D. Kim, H. Li, Y. Han, J. Jeong, H. Lee, and J.-H. Ryu, “Modulation of Inducible Nitric Oxide Synthase Expression in LPS-Stimulated BV-2 Microglia by Prenylated Chalcones from Cullen corylifolium (L.) Medik. through Inhibition of IκBα Degradation,” Molecules, vol. 23, no. 1, p. 109, 2018.

[15] M. H. Lee, J. Y. Kim, and J. H. Ryu, “Prenylflavones from Psoralea corylifolia inhibit nitric oxide synthase expression through the inhibition of IκBα degradation in activated microglial cells,” Biological and Pharmaceutical Bulletin, vol. 28, no. 12, pp. 2253–2257, 2005.

[16] H. J. Shin, D. H. Shon, and H. S. Youn, “Isobavachalcone Suppresses Expression of Inducible Nitric Oxide Synthase Induced by Toll-like Receptor Agonists,” International Immunopharmacology, vol. 15, no. 1, pp. 38–41, 2013.

[17] G. J. Lee, I. A. Cho, K. R. Kang et al., “Biological effects of the herbal plant-derived phytoestrogen Bavachin in primary rat chondrocytes,” Biological and Pharmaceutical Bulletin, vol. 38, no. 8, pp. 1199–1207, 2015.

[18] Y.-L. Hung, S.-C. Wang, K. Suzuki et al., “Bavachin attenuates LPS-induced inflammatory response and inhibits the activation of NLRP3 inflamasomes in macrophages,” Phyto- medicine, vol. 59, article 152785, 2019.

[19] C. C. Cheng, Y. H. Chen, W. L. Chang et al., “Phytoestrogen bavachin mediates anti-inflammation targeting IκB kinase-IκBα- NF-κB signaling pathway in chondrocytes in vitro,” European Journal of Pharmacology, vol. 636, no. 1-3, pp. 181–188, 2010.

[20] K. M. Lee, J. M. Kim, E. J. Baik, J. H. Ryu, and S. H. Lee, “Isobavachalcone attenuates lipopolysaccharide-induced ICAM-1 expression in brain endothelial cells through blockade of toll-like receptor 4 signaling pathways,” European Journal of Pharmacology, vol. 754, pp. 11–18, 2015.

[21] E. Szliszka, D. Skaba, Z. P. Czuba, and W. Krol, “Inhibition of inflammatory mediators by neobavaisoflavone in activated RAW264.7 macrophages,” Molecules, vol. 16, no. 5, pp. 3701–3712, 2011.

[22] S. W. Lee, B. R. Yun, M. H. Kim et al., “Phenolic compounds isolated from Psoralea corylifolia inhibit IL−6-induced STAT3 activation,” Planta Medica, vol. 78, no. 9, pp. 903–906, 2012.

[23] M. Nepal, H. J. Choi, B.-Y. Choi et al., “Anti-angiogenic and anti-tumor activity of Bavachinin by targeting hypoxia-inducible factor-1α,” European Journal of Pharmacology, vol. 691, no. 1-3, pp. 28–37, 2012.

[24] S. Rey and G. L. Semenza, “Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling,” Cardiovascular Research, vol. 86, no. 2, pp. 236–242, 2010.

[25] G. M. Tannahill, A. M. Curtis, J. Adamik et al., “Succinate is an inflammatory signal that induces IL−1β through HIF-1α,” Nature, vol. 496, no. 7444, pp. 238–242, 2013.

[26] A. Palazon, A. W. Goldrath, V. Nizet, and R. S. Johnson, “HIF Transcription Factors, Inflammation, and Immunity,” Immunity, vol. 41, no. 4, pp. 518–528, 2014.

[27] C. T. Taylor and S. P. Colgan, “Regulation of immunity and inflammation by hypoxia in immunological niches,” Nature Reviews Immunology, vol. 17, no. 12, pp. 774–785, 2017.

[28] E. M. Palsson-McDermott, A. M. Curtis, G. Goel et al., “Pyruvate Kinase M2 Regulates Hif-1α Activity and IL-1β Induction and Is a Critical Determinant of the Warburg Effect in LPS-Activated Macrophages,” Cell Metabolism, vol. 21, no. 1, pp. 65–80, 2015.

[29] I. Warbrick and S. W. Rabkin, “Hypoxia-inducible factor 1-alpha (HIF-1α) as a factor mediating the relationship between obesity and heart failure with preserved ejection fraction,” Obesity Reviews, vol. 20, no. 5, pp. 701–712, 2019.

[30] D. Gao, F. Liu, Z. Li, and Y. Guan, “Isobavachalcone attenuates Sephadex-induced lung injury via activation of A20 and NRF2/HO-1 in rats,” European Journal of Pharmacology, vol. 848, pp. 49–54, 2019.
[31] J. Hur, M. Kim, S. Y. Choi, Y. Jang, and T. Y. Ha, “Isobavachalcone attenuates myocyte atrophy induced by TNF-α through muscle atrophy F-box signaling and the nuclear factor erythroid 2-related factor 2 cascade,” *Phytotherapy Research*, vol. 33, no. 2, pp. 403–411, 2019.

[32] E. H. Kobayashi, T. Suzuki, R. Funayama et al., “Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription,” *Nature Communications*, vol. 7, no. 1, article 11624, 2016.

[33] C. J. Schmidlin, M. B. Dodson, L. Madhavan, and D. D. Zhang, “Redox regulation by NRF2 in aging and disease,” *Free Radical Biology & Medicine*, vol. 134, pp. 702–707, 2019.

[34] D. R. Bruns, J. C. Drake, L. M. Biela, F. F. Peelor, B. F. Miller, and K. L. Hamilton, “Nrf2 signaling and the slowed aging phenotype: evidence from long-lived models,” *Oxidative Medicine and Cellular Longevity*, vol. 2015, 15 pages, 2015.

[35] A. M. Kuhn, N. Tzieply, M. V. Schmidt et al., “Antioxidant signaling via Nrf2 counteracts lipopolysaccharide-mediated inflammatory responses in foam cell macrophages,” *Free Radical Biology and Medicine*, vol. 50, no. 10, pp. 1382–1391, 2011.

[36] A. Silva-Palacios, M. Königsberg, and C. Zazueta, “Nrf2 signaling and redox homeostasis in the aging heart: a potential target to prevent cardiovascular diseases?,” *Aging Research Reviews*, vol. 26, pp. 81–95, 2016.

[37] L. Fão, S. I. Mota, and A. C. Rego, “Shaping the Nrf2-ARE-related pathways in Alzheimer’s and Parkinson’s diseases,” *Aging Research Reviews*, vol. 54, article 100942, 2019.

[38] M. L. Ferrándiz, J. Nacher-Juan, and M. J. Alcaraz, “Nrf2 as a therapeutic target for rheumatic diseases,” *Biochemical Pharmacology*, vol. 152, pp. 338–346, 2018.

[39] X. Liu, X. Zhang, Y. Ding et al., “Nuclear factor E2-related factor-2 negatively regulates NLRP3 inflammasome activity by inhibiting reactive oxygen species-induced NLRP3 priming,” *Antioxidants & Redox Signaling*, vol. 26, no. 1, pp. 28–43, 2017.

[40] Y. Hou, Y. Wang, Q. He et al., “Nrf2 inhibits NLRP3 inflammasome activation through regulating Trxl/TNX1P complex in cerebral ischemia reperfusion injury,” *Behavioural Brain Research*, vol. 336, pp. 32–39, 2018.

[41] R. Venugopal and A. K. Jaiswal, “Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H-quinone oxidoreductase1 gene,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 25, pp. 14960–14965, 1996.

[42] Y. Yuan, S. Ling, and J. W. Xu, “4’-O-methylbavachalcone protects ischemic stroke through inhibiting pyroptosis by targeting NLRP3/GSDMD axis in mice,” In preparation.

[43] D. Zhang, J. Qian, P. Zhang et al., “Gasdermin D serves as a key executor of pyroptosis in experimental cerebral ischemia and reperfusion model both in vivo and in vitro,” *Journal of Neuroscience Research*, vol. 97, no. 6, pp. 645–660, 2019.

[44] J. Li, J. H. Hao, D. Yao et al., “Caspase-1 inhibition prevents neuronal death by targeting the canonical inflammasome pathway of pyroptosis in a murine model of cerebral ischemia,” *CNS Neuroscience & Therapeutics*, 2020.

[45] H. Lee, H. Li, M. Noh, and J. H. Ryu, “Bavachin from *Psoralea corylifolia* improves insulin-dependent glucose uptake through insulin signaling and AMPK activation in 3T3-L1 adipocytes,” *International Journal of Molecular Sciences*, vol. 17, no. 4, 2016.

[46] A. Croasdell, P. F. Duffney, N. Kim, S. H. Lacy, P. J. Sime, and R. P. Phipps, “PPARγ and the Innate Immune System Mediate the Resolution of Inflammation,” *PPAR Research*, vol. 2015, 20 pages, 2015.

[47] T. M. De Silva, Y. Li, D. A. Kinzenbaw, C. D. Sigmund, and F. M. Faraci, “Endothelial PPARγ (peroxisome proliferator-activated receptor-γ) is essential for preventing endothelial dysfunction with aging,” *Hypertension*, vol. 72, no. 1, pp. 227–234, 2018.

[48] M. L. Modrick, D. A. Kinzenbaw, Y. Chu, C. D. Sigmund, and F. M. Faraci, “Peroxisome proliferator-activated receptor-γ protects against vascular aging,” *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*, vol. 302, no. 10, pp. R1184–R1190, 2012.

[49] S. Lim, K.-S. Lee, J. E. Lee et al., “Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis,” *Atherosclerosis*, vol. 243, no. 1, pp. 107–119, 2015.

[50] A. Briot, P. Decaunes, F. Volat et al., “Senescence alters PPARγ (peroxisome proliferator-activated receptor gamma)-dependent fatty acid handling in human adipose tissue microvascular endothelial cells and favors inflammation,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 38, no. 5, pp. 1134–1146, 2018.

[51] A. K. Gebremeskel, T. D. Wijerathne, J. H. Kim et al., “Psoralea corylifolia extract induces vasodilation in rat arteries through both endothelium-dependent and -independent mechanisms involving inhibition of TRPC3 channel activity and elaboration of prostaglandin,” *Pharmacological Biology*, vol. 55, no. 1, pp. 2136–2144, 2016.

[52] W. J. Tsai, W. C. Hsin, and C. C. Chen, “Antiplatelet Flavonoids from Seeds of *Psoralea corylifolia*,” *Journal of Natural Products*, vol. 59, no. 7, pp. 671–672, 1996.

[53] M. Bhatti, S. Ayton, O. Michail et al., “Effect of Bruton’s tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction,” *Thrombosis Research*, vol. 179, pp. 64–68.

[54] L. Yang, X. Chen, S. Wang et al., “N2 extenuates experimental ischemic stroke through platelet aggregation inhibition,” *Thrombosis Research*, vol. 136, no. 6, pp. 1310–1317, 2015.

[55] X. H. Yu, Y. C. Fu, D. W. Zhang, K. Yin, and C. K. Tang, “Foam cells in atherosclerosis,” *Clinica Chimica Acta*, vol. 424, pp. 245–252, 2013.

[56] M. A. Rogers, J. Liu, B.-L. Song, B.-L. Li, C. Y. Chang, and T.-Y. Chang, “Acyl-CoA cholesterol acyltransferases (ACATs/SOATs): enzymes with multiple sterols as substrates and as activators,” *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 151, pp. 102–107, 2015.

[57] Y. Dang, S. Ling, J. Ma, R. Ni, and J.-W. Xu, “Bavachalcone enhances RORα expression, controls Bmal1 circadian transcription, and depresses cellular senescence in human endothelial cells,” *Evidence-based Complementary and Alternative Medicine*, vol. 2015, Article ID 920431, 11 pages, 2015.

[58] Y. Dang, S. Ling, J. Duan, J. Ma, R. Ni, and J.-W. Xu, “Bavachalcone-induced manganese superoxide dismutase expression through the AMP-activated protein kinase pathway in human endothelial cells,” *Pharmacology*, vol. 95, no. 3-4, pp. 105–110, 2015.
Oxidative Medicine and Cellular Longevity

[59] S. Ling, R. Z. Ni, Y. Yuan et al., “Natural compound bavachalcone promotes the differentiation of endothelial progenitor cells and neovascularization through the ROSA-erythropoietin-AMPK axis,” Oncotarget, vol. 8, no. 49, pp. 86188–86205, 2017.

[60] E. H. Bahlmann, K. de Groot, J.-M. Spandau et al., “Erythropoietin regulates endothelial progenitor cells,” Blood, vol. 103, no. 3, pp. 921–926, 2004.

[61] M. Ferrario, M. Massa, V. Rosti et al., “Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction,” European Heart Journal, vol. 28, no. 15, pp. 1805–1813, 2007.

[62] M. Hoch, P. Fischer, B. Stapel et al., “Erythropoietin preserves the endothelial differentiation capacity of cardiac progenitor cells and reduces heart failure during anticancer therapies,” Cell Stem Cell, vol. 9, no. 2, pp. 131–143, 2011.

[63] L. Wang, X. Wang, H. Su et al., “Recombinant human erythropoietin improves the neurofunctional recovery of rats following traumatic brain injury via an increase in circulating endothelial progenitor cells,” Translational Stroke Research, vol. 6, no. 6, pp. 50–59, 2015.

[64] Y. Xu, Y. Tian, H. J. Wei et al., “Erythropoietin increases circulating endothelial progenitor cells and reduces the formation and progression of cerebral aneurysm in rats,” Neurosciences, vol. 181, pp. 292–299, 2011.

[65] D. Kukidome, T. Nishikawa, K. Sonoda et al., “Activation of AMP-Activated Protein Kinase Reduces Hypoglycemia-Induced Mitochondrial Reactive Oxygen Species Production and Promotes Mitochondrial Biogenesis in Human Umbilical Vein Endothelial Cells,” Diabetes, vol. 55, no. 1, pp. 120–127, 2005.

[66] S. Kröller-Schön, T. Jansen, F. Hauptmann et al., “a1AMPK-Activated protein kinase mediates vascular protective effects of exercise,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 7, pp. 1632–1641, 2012.

[67] Z. Chen, I. C. Peng, W. Sun et al., “AMP-Activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633,” Circulation Research, vol. 104, no. 4, pp. 496–505, 2009.

[68] J. Brandauer, M. A. Andersen, H. Kellezi et al., “AMP-Activated protein kinase controls exercise training- and AICAR-induced increases in SIRT3 and MnSOD,” Frontiers in Physiology, vol. 6, 2015.

[69] X. Li, Y. Han, W. Pang et al., “AMP-activated protein kinase promotes the differentiation of endothelial progenitor cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 10, pp. 1789–1795, 2008.

[70] V. M. Mendoza-Núñez, J. Rosado-Pérez, E. Santiago-Osorio, R. Ortiz, M. A. Sánchez-Rodríguez, and R. E. Galván-Duarte, “Aging linked to type 2 diabetes increases oxidative stress and chronic inflammation,” Rejuvenation Researcher, vol. 14, no. 1, pp. 25–31, 2011.

[71] M. K. Figaro, S. B. Kritchovsky, H. E. Resnick et al., “Diabetes, Inflammation, and Functional Decline in Older Adults: Findings from the Health, Aging and Body Composition (ABC) study,” Diabetes Care, vol. 29, no. 9, pp. 2039–2045, 2006.

[72] Y. Hasegawa, T. Saito, T. Ogihara et al., “Blockade of the nuclear factor-kB pathway in the endothelium prevents insulin resistance and prolongs life spans,” Circulation, vol. 125, no. 9, pp. 1122–1133, 2012.

[73] L. C. Bailey-Downs, Z. Tucsek, P. Toth et al., “Aging Exacerbates Obesity-Induced Oxidative Stress and Inflammation in Perivascular Adipose Tissue in Mice: A Paracrine Mechanism Contributing to Vascular Redox Dysregulation and Inflammation,” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, vol. 68, no. 7, pp. 780–792, 2013.

[74] J. Liu, Y. Zhao, C. Huang, Y. Li, and F. Guo, “Preynlated flavonoid-standardized extract from seeds of Psoralea corylolia L. activated fat browning in high-fat diet-induced obese mice,” Phytotherapy Research, vol. 33, no. 7, pp. 1851–1864, 2019.

[75] C. S. Truong, E. Seo, and H. S. Jun, “Psoralea corylolia L. Seed Extract Attenuates Methylyglyoxal-Induced Insulin Resistance by Inhibition of Advanced Glycation End Product Formation,” Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 4310319, 14 pages, 2019.

[76] E. Seo, Y. S. Oh, and H. S. Jun, “Psoralea corylolia L. Seed Extract Attenuates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice,” Nutrients, vol. 8, no. 2, p. 83, 2016.

[77] C. B. Shrikanth and C. D. Nandini, “AMPK in microvascular complications of diabetes and the beneficial effects of AMPK activators from plants,” Phytomedicine, vol. 73, 2020.

[78] T. Joshi, A. K. Singh, P. Haratipour et al., “Targeting AMPK signaling pathway by natural products for treatment of diabetes mellitus and its complications,” Journal of Cellular Physiology, vol. 234, no. 10, pp. 17212–17231, 2019.

[79] G. Du, L. Feng, Z. Yang et al., “Separation and peroxisome proliferator-activated receptor-γ agonist activity evaluation of synthetic racemic bavachavinin enantiomers,” Bioorganic & Medicinal Chemistry Letters, vol. 25, no. 12, pp. 2579–2583, 2015.

[80] L. Feng, H. Luo, Z. Xu et al., “Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-γ and PPAR-α agonists on carbohydrate and lipid metabolism in db/db and diet-induced obese mice,” Diabetologia, vol. 59, no. 6, pp. 1276–1286, 2016.

[81] H. Lee, H. Li, M. Kweon, Y. Choi, M. Kim, and J.-H. Ryu, “Isobavachalcone from Angelica keiskei inhibits adipogenesis and prevents lipid accumulation,” International Journal of Molecular Sciences, vol. 19, no. 6, 2018.

[82] Q. X. Yu, Y. Hu, G. Y. Li, W. Xu, Y. T. Zhang, and X. W. Yang, “Multi-target anti-Alzheimer activities of four prenylated compounds from Psoralea fruticosa,” Molecules, vol. 23, no. 3, 2018.

[83] X. Chen, Y. Yang, and Z. Zhang, “Isobavachalcone and bavachinin from Psoraleae Fructusmodulate Ap42 aggregation process through different mechanisms in vitro,” FEBS Letters, vol. 587, no. 18, pp. 2930–2935, 2013.

[84] H. Jing, S. Wang, M. Wang, W. Fu, C. Zhang, and D. Xu, “Isobavachalcone attenuates MPTP-induced Parkinson’s disease in mice by inhibition of microglial activation through NF-kB pathway,” PLoS One, vol. 12, no. 1, article e0169560, 2017.

[85] Y. Kim, H.-S. Lim, J. Lee, and S.-J. Jeong, “Quantitative analysis of Psoralea corylolia Linne and its neuroprotective and anti-neuroinflammatory effects in HT22 hippocampal cells and BV-2 microglia,” Molecules, vol. 21, no. 8, 2016.

[86] N. O. Zarmouh, E. A. Mazzio, F. M. Elshami, S. S. Messeha, S. V. K. Eyunn, and K. F. A. Soliman, “Evaluation of the inhibitory effects of bavachinin and bavachin on human monoamine oxidases A and B,” Evidence-based Complementary
K. L. Chang, L. R. Wong, H. N. Pee, S. Yang, and P. C.-L. Ho, H. L. Martin, R. B. Mounsey, S. Mustafa, K. Sathe, and P. C. Chen, M. R. Vargas, A. K. Pani et al., L. P. Quinn, B. Crook, M. E. Hows et al., Y. Luo, W. Yin, A. P. Signore et al., Z. Ou, X. Zhao, L. A. Labiche et al., E. Hamel, and H. N. Pee, “Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-β agonist rosiglitazone,” Journal of Neurochemistry, vol. 97, no. 2, pp. 435–448, 2006.

Z. Ou, X. Zhao, L. A. Labiche et al., “Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARγ) and 15d-prostaglandin J2–Mediated protection of brain after experimental cerebral ischemia in rat,” Brain Research, vol. 1096, no. 1, pp. 196–203, 2006.

C. K. Combs, D. E. Johnson, J. C. Karlo, S. B. Cannady, and G. E. Landreth, “Inflammatory mechanisms in Alzheimer’s disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists,” Journal of Neuroscience, vol. 20, no. 2, pp. 558–567, 2000.

A. Badhwar, R. Brown, D. B. Stanimirovic, A. S. Haqqani, and E. Hamel, “Proteomic differences in brain vessels of Alzheimer’s disease mice: normalization by PPARγ agonist pioglitazone,” Journal of Cerebral Blood Flow & Metabolism, vol. 37, no. 3, pp. 1120–1136, 2017.

K. L. Chang, L. R. Wong, H. N. Lee, S. Yang, and P. C.-L. Ho, “Reversing metabolic dysfunction in cortex and cerebellum of APP/PS1 mice, a model for Alzheimer’s disease by pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist,” Molecular Neurobiology, vol. 56, no. 11, pp. 7267–7283, 2019.

L. P. Quinn, B. Crook, M. E. Hows et al., “The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson’s disease through inhibition of monoamine oxidase B,” British Journal of Pharmacology, vol. 154, no. 1, pp. 226–233, 2008.

H. L. Martin, R. B. Mounsey, S. Mustafa, K. Sathe, and P. Teismann, “Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson’s disease,” Experimental Neurology, vol. 235, no. 2, pp. 528–538, 2012.

D. Lecca, E. Janda, G. Mulas et al., “Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson’s disease models,” British Journal of Pharmacology, vol. 175, no. 16, pp. 3298–3314, 2018.

K. Trinh, L. Andrews, J. Krause et al., “Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson’s disease through an NRFR2-dependent mechanism,” Journal of Neuroscience, vol. 30, no. 16, pp. 5525–5532, 2010.

P. C. Chen, M. R. Vargas, A. K. Pani et al., “Nrfr2-mediated neuroprotection in the MPTP mouse model of Parkinson’s disease: critical role for the astrocyte,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 8, pp. 2933–2938, 2009.

S. Li, X. Zhao, P. Lazarovic, and W. Zheng, “Artether activation of AMPK/GSK3β (ser9)/Nrfr2 signaling confers neuroprotection towards β-amyloid-induced neurotoxicity in 3xTg Alzheimer’s mouse model,” Oxidative Medicine and Cellular Longevity, vol. 2019, 24 pages, 2019.

F. Morroni, G. Sita, A. Graziosi et al., “Neuroprotective effect of caffeic acid phenethyl ester in a mouse model of Alzheimer’s disease involves Nrfr2/HO-1 pathway,” Aging and Disease, vol. 9, no. 4, pp. 605–622, 2018.

K. Gao, M. Liu, Y. Ding et al., “A phenolic amide (LyA) isolated from the fruits of Lycium barbarum protects against cerebral ischemia–reperfusion injury via PKC/Nrf2/HO-1 pathway,” Aging (Albany NY), vol. 11, no. 24, pp. 12361–12374, 2019.

K. Gao, M. Liu, Y. Ding et al., “A phenolic amide (LyA) isolated from the fruits of Lycium barbarum protects against cerebral ischemia–reperfusion injury via PKC/Nrf2/HO-1 pathway,” Aging (Albany NY), vol. 11, no. 24, pp. 12361–12374, 2019.

K. Gao, M. Liu, Y. Ding et al., “A phenolic amide (LyA) isolated from the fruits of Lycium barbarum protects against cerebral ischemia–reperfusion injury via PKC/Nrf2/HO-1 pathway,” Aging (Albany NY), vol. 11, no. 24, pp. 12361–12374, 2019.

K. Gao, M. Liu, Y. Ding et al., “A phenolic amide (LyA) isolated from the fruits of Lycium barbarum protects against cerebral ischemia–reperfusion injury via PKC/Nrf2/HO-1 pathway,” Aging (Albany NY), vol. 11, no. 24, pp. 12361–12374, 2019.

K. Gao, M. Liu, Y. Ding et al., “A phenolic amide (LyA) isolated from the fruits of Lycium barbarum protects against cerebral ischemia–reperfusion injury via PKC/Nrf2/HO-1 pathway,” Aging (Albany NY), vol. 11, no. 24, pp. 12361–12374, 2019.

K. Gao, M. Liu, Y. Ding et al., “A phenolic amide (LyA) isolated from the fruits of Lycium barbarum protects against cerebral ischemia–reperfusion injury via PKC/Nrf2/HO-1 pathway,” Aging (Albany NY), vol. 11, no. 24, pp. 12361–12374, 2019.
[112] K. Prass, A. Scharff, K. Ruscher et al., "Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin," Stroke, vol. 34, no. 8, pp. 1981–1986, 2003.

[113] K. Liu, T. Sun, P. Wang, Y. H. Liu, L. W. Zhang, and Y. X. Xue, "Effects of erythropoietin on blood-brain barrier tight junctions in ischemia-reperfusion rats," Journal of Molecular Neuroscience, vol. 49, no. 2, pp. 369–379, 2013.

[114] K. Y. Z. Zheng, R. C. Y. Choi, A. W. H. Cheung et al., "Flavonoids from Radix Astragali induce the expression of erythropoietin in cultured cells: a signaling mediated via the accumulation of hypoxia-inducible factor-1α," Journal of Agricultural and Food Chemistry, vol. 59, no. 5, pp. 1697–1704, 2011.

[115] X. M. Wu, Z. M. Qian, L. Zhu et al., "Neuroprotective effect of ligustilide against ischaemia-reperfusion injury via up-regulation of erythropoietin and down-regulation of RTP801," British Journal of Pharmacology, vol. 164, no. 2, pp. 332–343, 2011.

[116] Y. Y. Sun, S. H. Lin, H. C. Lin et al., "Cell type-specific dependency on the PI3K/Akt signaling pathway for the endogenous Epo and VEGF induction by baicalin in neurons versus astrocytes," PLoS One, vol. 8, no. 7, article e69019, 2013.

[117] Y. Kodama, Y. Takeuchi, M. Suzawa et al., "Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6); relationship to osteopenia with enhanced adipogenesis," Journal of Bone and Mineral Research, vol. 13, no. 9, pp. 1370–1377, 1998.

[118] J. O. Nehlin, A. Jafari, M. Tencercova, and M. Kassem, "Aging and lineage allocation changes of bone marrow skeletal (stromal) stem cells," Bone, vol. 123, pp. 265–273, 2019.

[119] J. N. Farr, D. G. Fraser, H. Wang et al., "Identification of senescent cells in the bone microenvironment," Journal of Bone and Mineral Research, vol. 31, no. 11, pp. 1920–1929, 2016.

[120] J. N. Farr, M. Xu, M. M. Weivoda et al., "Targeting cellular senescence prevents age-related bone loss in mice," Nature Medicine, vol. 23, no. 9, pp. 1072–1079, 2017.

[121] M. Piemontese, M. Almeida, A. G. Robling et al., "Old age causes de novo intracortical bone remodeling and porosity in mice," JCI Insight, vol. 2, no. 17, 2017.

[122] X. Sun, B. Zhang, X. Pan et al., "Ocyt lutein inhibits osteoclastogenesis by suppressing Hrd1 and activating Nr2 signaling," The FASEB Journal, vol. 33, no. 11, pp. 12929–12940, 2019.

[123] W. Yin, S. Liu, M. Dong et al., "A new NLRP3 inflammasome inhibitor, dioscin, promotes osteogenesis," Small, vol. 16, no. 1, article e905977, 2020.

[124] H. S. Son, J. Lee, H. I. Lee et al., "Benzydamine inhibits osteoclast differentiation and bone resorption via down-regulation of interleukin-1β expression," Acta Pharmaceutica Sinica B, vol. 10, no. 3, pp. 462–474, 2020.

[125] D. Xin, H. Wang, J. Yang et al., "Phytoestrogens from Psorala corylifolia reveal estrogen receptor-subtype selectivity," Phytomedicine, vol. 17, no. 2, pp. 126–131, 2010.

[126] W. D. Li, C. P. Yan, Y. Wu et al., "Osteoblasts proliferation and differentiation stimulating activities of the main components of Fructus _Psoraleae corylifoliae_;_ Phytomedicine, vol. 21, no. 4, pp. 400–405, 2014.

[127] Z. B. Weng, Q. Q. Gao, F. Wang et al., "Positive skeletal effect of two ingredients of Psoralea corylifolia L. on estrogen deficiency-induced osteoporosis and the possible mechanisms of action," Molecular and Cellular Endocrinology, vol. 417, pp. 103–113, 2015.

[128] L. Song, M. Liu, N. Ono, F. R. Brinthurst, H. M. Kronenberg, and J. Guo, "Loss of wnt/β-catenin signaling causes cell fate shift of preosteoblasts from osteoblasts to adipocytes," Journal of Bone and Mineral Research, vol. 27, no. 11, pp. 2344–2358, 2012.

[129] C. N. Bennett, K. A. Longo, W. S. Wright et al., "Regulation of osteoblastogenesis and bone mass by Wnt10b," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 9, pp. 3324–3329, 2005.

[130] M. J. Don, L. C. Lin, and W. F. Chiou, "Neobavaisolavone stimulates osteogenesis via p38-mediated up-regulation of transcription factors and osteoid genes expression in MC3T3-E1 cells," Phytomedicine, vol. 19, no. 6, pp. 551–561, 2012.

[131] C. A. de Frutos, R. Dacquin, S. Vega, P. Juridic, I. Machuca-Gayet, and M. Angela Nieto, "Snail1 controls bone mass by regulating Runx2 and VDR expression during osteoblast differentiation," The EMBO Journal, vol. 28, no. 6, pp. 686–696, 2009.

[132] I. Tosa, D. Yamada, M. Yasumatsu et al., "Postnatal Runx2 deletion leads to low bone mass and adipocyte accumulation in mice bone tissues," Biochemical and Biophysical Research Communications, vol. 516, no. 4, pp. 1229–1233, 2019.

[133] Y. Yang, Y. Huang, L. Zhang, and C. Zhang, "Transcriptional regulation of bone sialoprotein gene expression by Oxa," Biochemical and Biophysical Research Communications, vol. 476, no. 4, pp. 574–579, 2016.

[134] L. Ge, K. Cheng, and J. Han, "A network pharmacology approach for uncovering the osteogenic mechanisms of Psoralea corylifolia Linn," Evidence-based Complementary and Alternative Medicine, vol. 2019, 10 pages, 2019.

[135] C. K. Park, Y. Lee, E. J. Chang et al., "Bavachalcone inhibits osteoclast differentiation through suppression of NFATc1 induction by RANKL," Biochemical Pharmacology, vol. 75, no. 11, pp. 2175–2182, 2008.

[136] A. O. Aliprantis, Y. Ueki, R. Sulyanto et al., "NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in chimerism," The Journal of Clinical Investigation, vol. 118, no. 11, pp. 3775–3789, 2008.

[137] K. Kim, J. H. Kim, J. Lee et al., "Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis," The Journal of Biological Chemistry, vol. 280, no. 42, pp. 35209–35216, 2005.

[138] E. M. Grüssinger, M. Kang, L. Bouchareychas et al., "Ca2+-dependent regulation of NFATc1 via KCa3.1 in inflammatory osteoclastogenesis," The Journal of Immunology, vol. 200, no. 2, pp. 749–757, 2018.

[139] J. Y. Kim, J. Y. Min, J. M. Baek et al., "CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling _in vitro_ and RANKL-induced calvarial bone destruction _in vivo_;_ Bone, vol. 79, pp. 242–251, 2015.

[140] N. Yamaguchi, T. Kukita, Y. J. Li et al., "Adiponectin inhibits induction of TNF-α/RANKL-stimulated NFATc1 via the AMPK signaling," FEBS Letters, vol. 582, no. 3, pp. 451–456, 2008.

[141] N. K. Shevde, A. C. Bendixen, K. M. Dienger, and J. W. Pike, "Estrogens suppress RANK ligand-induced osteoclast..."
differentiation via a stromal cell independent mechanism involving c-jun repression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 14, pp. 7829–7834, 2000.

[142] S. Srivastava, G. Toraldo, M. N. Weitzmann, S. Cenci, F. P. Ross, and R. Pacifici, “Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-κB ligand (RANKL)-induced JNK activation,” The Journal of Biological Chemistry, vol. 276, no. 12, pp. 8836–8840, 2001.

[143] V. García Palacios, L. J. Robinson, C. W. Borysenko, T. Lehmann, S. E. Kalla, and H. C. Blair, “Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 cells by estrogen and phytoestrogens,” The Journal of Biological Chemistry, vol. 280, no. 14, pp. 13720–13727, 2005.